Skip Navigation

A Phase II Trial of Sacituzumab Govitecan IMMU-132 NSC 820016 for Patients with HER2-Negative Breast Cancer and Brain Metastases

Brief Summary

Type:
Breast Cancer

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT04647916

Study #:
STUDY00147029

Start Date:
Aug 15, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04647916

View Complete Trial Details & Eligibility at ClinicalTrials.gov